Showing 2261-2270 of 5623 results for "".
- Research: Protein Deletion Could Treat Age and Diabetes-Induced Eye Diseaseshttps://modernod.com/news/research-protein-deletion-could-treat-age-and-diabetes-induced-eye-diseases/2481627/Researchers at the Wayne State University School of Medicine in Detroit say they have provided evidence that depletion of a certain protein in the body can treat age and diabetes-induced retinal diseases, according to a university news release. The protein, called vascular cell ad
- Alimera Acquires US Commercial Rights to Yutiqhttps://modernod.com/news/alimera-acquires-us-commercial-rights-to-yutiq/2481624/Alimera Sciences has acquired additional commercialization rights for Yutiq (fluocinolone acetonide intravitreal insert, 0.18mg) for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals. Alimera now has exclusi
- Delta Gamma Foundation Awards RestoringVision with Grant to Serve People in Need of Vision Services and Eyeglasses in the UShttps://modernod.com/news/delta-gamma-foundation-awards-restoringvision-with-grant-to-serve-people-in-need-of-vision-services-and-eyeglasses-in-the-us/2481609/RestoringVision, a global nonprofit, recently won its third Service for Sight grant from the Delta Gamma Foundation. The funding will support bringing vision services and eyeglasses to 270,000 low-income people in the United States, according to RestoringVision. The award supports
- Trefoil’s TTHX1114 Improves Rate of Visual Recovery After Descemet Stripping Only (DSO) in Phase 2 STORM Datahttps://modernod.com/news/trefoils-investigational-candidate-tthx1114-improves-rate-of-visual-recovery-after-descemet-stripping-only-dso-in-phase-2-storm-data-presented-at-ascrs/2481605/Trefoil Therapeutics announced that TTHX1114 was found to improve the rate of visual recovery and corneal deturgescence (state of relative dehydration maintained by the normal cornea that is necessary for transparency) after Descemet Stripping Only (DSO) in a dose-responsive manner in the ph
- Precision Eye Therapy for Dogs Ready for Human Clinical Developmenthttps://modernod.com/news/precision-eye-therapy-for-dogs-ready-for-human-clinical-development/2481576/A successful gene therapy trialed at Michigan State University in dogs with an inherited eye disease is ready to be developed for clinical use in human patients with retinitis pigmentosa, according to a university news release. Simon Petersen-Jones, professor and Donald R. Myers and Wil
- EssilorLuxottica Unveils 4-Year Clinical Trial Results of its Essilor Stellest Lens athttps://modernod.com/news/essilorluxottica-unveils-4-year-clinical-trial-results-of-its-essilor-stellest-lens-at-arvo-at/2481572/EssilorLuxottica presented the 4-year clinical trial results of its Essilor Stellest lens for myopia control at the 2023 ARVO annual meeting in New Orleans. The findings show that Essilor Stellest lenses continue to exhibit strong efficacy in slowing myopia progression and axial ey
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- New Trefoil Therapeutics’ Data Presented at ARVO Demonstrate that TTHX1114 Controls Edema in At-Risk Patients Undergoing Cataract Surgeryhttps://modernod.com/news/new-trefoil-therapeutics-data-presented-at-arvo-demonstrate-that-tthx1114-controls-edema-in-at-risk-patients-undergoing-cataract-surgery/2481556/Trefoil Therapeutics announced a series of data presentations demonstrating the potential use of TTHX1114 to protect endothelial cells at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The company also announced the completion of the phase 1 epithel
- Bausch + Lomb Announces U.S. Launch of StableVisc Cohesive Ophthalmic Viscosurgical Device and TotalVisc Viscoelastic Systemhttps://modernod.com/news/bausch-lomb-announces-us-launch-of-stablevisc-cohesive-ophthalmic-viscosurgical-device-and-totalvisc-viscoelastic-system/2481555/Bausch + Lomb announced the US launch of StableVisc cohesive ophthalmic viscosurgical device (OVD) and the TotalVisc Viscoelastic System. StableVis
- One Million Patients Measured on the Neurolens Measurement Devicehttps://modernod.com/news/one-million-patients-measured-on-the-neurolens-measurement-device/2481546/Neurolens announced that 1 million patients have been measured on the Neurolens Measurement Device, an eye tracking system that can identify eye misalignment as small as 0.01 prism diopters. Given the sharp acceleration in remote working and learning, optometrists have reported record number